Goat anti luciferase antibody

Manufactured by Promega

The Goat anti-luciferase antibody is a laboratory reagent produced by Promega. It is a polyclonal antibody raised in goats against the luciferase enzyme. This antibody can be used in various immunoassays and detection methods to specifically recognize and bind to luciferase proteins.

Automatically generated - may contain errors

Lab products found in correlation

Rituximab, by Genentech (1 mentions) Rabbit anti cleaved caspase 3 antibody, by Cell Signaling Technology (1 mentions) D luciferin, by Promega (1 mentions) Cyclophosphamide, by Bristol-Myers Squibb (1 mentions) Anti pcna antibody, by Abcam (1 mentions) Alexa fluor 488, by Thermo Fisher Scientific (1 mentions) Alexa fluor 594, by Thermo Fisher Scientific (1 mentions) Rabbit anti hif 1α antibody, by Novus Biologicals (1 mentions) Vector dab, by Vector Laboratories (1 mentions) Anti α sma, by Abcam (1 mentions) Vectastain elite abc kit, by Vector Laboratories (1 mentions)

2 protocols using goat anti luciferase antibody

Apoptosis Induction Protocol for Cancer Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

d-luciferin, VivoGlo reagent, and goat anti-luciferase antibody were purchased from Promega. Navitoclax and venetoclax were synthesized at AbbVie as previously described (Park et al. 2008 (link); Souers et al. 2013 (link)). Cyclophosphamide was purchased from Bristol-Myers Squibb (Princeton, NJ). Doxorubicin was purchased from Bedford Laboratories (Bedford, OH). Vincristine was purchased from Mayne Pharmaceuticals (Paramus, NJ). Prednisolone was purchased from ETHEX Corp (St Louis, MO). Bendamustine was purchased from Cephalon Inc (Frazer, MA). Rituximab was purchased from Genentech (South San Francisco, CA). Phosal 50 PG was purchased from American Lecithin (Oxford, CT). Rabbit anti-cleaved caspase 3 antibody was purchased from Cell Signaling (Danvers, MA).

Ackler S., Oleksijew A., Chen J., Chyla B.J., Clarin J., Foster K., McGonigal T., Mishra S., Schlessinger S., Smith M.L., Tahir S.K., Leverson J.D., Souers A.J., Boghaert E.R, & Hickson J. (2015). Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacology Research & Perspectives, 3(5), e00178.

+ Open protocol

+ Expand

Multimodal Liver Tissue Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunofluorescence was used to detect and quantify type I collagen, neutrophils, and macrophages (i.e., CD68 and F4/80) in 8 μm frozen sections of liver, as described previously (12 (link)).
To detect GFAP and firefly luciferase (Photinus pyralis) or HIF-1α in frozen sections of liver, the sections were fixed in 4% formalin and then incubated with goat anti-luciferase antibody diluted 1:50 (Promega, Madison, WI) or rabbit anti-HIF-1α antibody (1:100, NB100-479, Novus Biologicals, Littleton, CA) and chicken anti-GFAP antibody diluted 1:50 (Aves Laboratories, Tigard, OR). The sections were then incubated with secondary antibodies conjugated to either Alexa Fluor 488 or Alexa Fluor 594 (Life Technologies, Grand Island, NY).
Proliferating cell nuclear antigen (PCNA) and α-smooth muscle actin (α-SMA) were detected in formalin-fixed, paraffin-embedded sections of liver using the Vectastain Elite ABC Kit and Vector DAB (Vector Laboratories, Burlingame, CA). Anti-PCNA antibody (1:8000, Abcam, Cambridge, MA) and anti-α-SMA (1:100, Abcam) were added to the tissues and incubated overnight at 4 degrees C.

Mochizuki A., Pace A., Rockwell C.E., Roth K.J., Chow A., O'Brien K.M., Albee R., Kelly K., Towery K., Luyendyk J.P, & Copple B.L. (2014). Hepatic Stellate Cells Orchestrate Clearance of Necrotic Cells in a HIF-1α-dependent Manner by Modulating Macrophage Phenotype in Mice. Journal of immunology (Baltimore, Md. : 1950), 192(8), 3847-3857.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!